Targeted drug trial offers hope for Tough-to-Treat ovarian cancer

NCT ID NCT05043922

Summary

This study is testing an experimental drug called CYH33 for women with a specific type of recurrent ovarian cancer (clear cell carcinoma) that has a particular genetic change (PIK3CA mutation). It is for patients whose cancer has come back or persisted after standard chemotherapy. The goal is to see if this targeted pill can shrink tumors and control the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beijing Obstetrics and Gynecology Hospital, Capital Medical University

    Beijing, China

  • Chinese PLA General Hospital

    Beijing, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Hokkaido University Hospital

    Sapporo, Japan

  • Hubei Cancer Hospital

    Hubei, China

  • Hunan Cancer Hospital

    Hunan, China

  • Jiangsu Province Hospital

    Nanjing, China

  • Jikei University Hospital

    Minato-Ku, Tokyo, Japan

  • Keio University Hospital

    Shinjuku-Ku, Tokyo, Japan

  • Kurume University Hospital

    Kurume, Fukuoka, Japan

  • Nagoya University Hospital

    Nagoya, Japan

  • National Cancer Center Hospital

    Chuo Ku, Tokyo, Japan

  • Niigata University Medical & Dental Hospital

    Niigata, Japan

  • Obstetrics & Gynecology Hospital of Fudan University

    Shanghai, China

  • Okayama University Hospital

    Okayama, Japan

  • Osaka University Hospital

    Suita, Osaka, Japan

  • Qilu Hospital of Shandong University

    Jinan, China

  • Qingdao Central Hospital

    Qingdao, China

  • Shanghai First Maternity and Infant Hospital

    Shanghai, China

  • Shikoku Cancer Center

    Matsuyama, Japan

  • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

    Zhejiang, China

  • Sun Yat-sen University Cancer Center

    Guangdong, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, China

  • The First Affiliated Hospital of Hainan Medical College

    Haikou, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangdong, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • The People's Hospital Of Guangxi Zhuang Autonomous Region

    Nanning, China

  • The Southwest Hospital of AMU

    Chongqing, China

  • The Third People's Hospital of Hainan Province

    Hainan, China

  • Tianjin Medical University General Hospital

    Tianjin, China

  • Tohoku University Hospital

    Sendai, Japan

  • West China Second University Hospital, Sichuan University

    Sichuan, China

  • Xiaohua wu

    Shanghai, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, China

Conditions

Explore the condition pages connected to this study.